Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next
Moderna shares fell about 2% to $33.60 early Monday after the company forecast $1.9 billion in 2025 revenue and cut its GAAP operating-expense outlook. CFO James Mock said U.S. retail vaccination rates dropped 26% year-on-year, helping sales hit the low end of forecasts. Moderna expects to end 2025 with about $8.1 billion in cash, including a planned $600 million loan draw. CEO Stéphane Bancel announced a $2 billion annual expense cut for 2025.